(Q38207456)

31 August 2017

title

Second-line chemotherapy in advanced biliary cancer: a systematic review (English)

1 reference

31 August 2017

1 reference

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Richard A Hubner

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

A Lamarca

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

W David Ryder

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

publication date

25 April 2014

1 reference

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

2328-2338

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24769639%20AND%20SRC:MED&resulttype=core&format=json

Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Carcinoma of the gallbladder. Histologic types, stage of disease, grade, and survival rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

21 January 2018

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

21 January 2018

SOR: project methodology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Improvement of prognosis for unresectable biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Phase II trial of oxaliplatin combined with leucovorin and fluorouracil for recurrent/metastatic biliary tract carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

S-1 monotherapy in patients with advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: a multicentre, multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162

A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU162